Astrogliosis as a therapeutic target for neurodegenerative diseases

[1]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[2]  J. Rothstein,et al.  Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. , 1992, The New England journal of medicine.

[3]  M. Hediger,et al.  Knockout of Glutamate Transporters Reveals a Major Role for Astroglial Transport in Excitotoxicity and Clearance of Glutamate , 1996, Neuron.

[4]  Robert G. Miller,et al.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). , 2007, The Cochrane database of systematic reviews.

[5]  I. Mizuta,et al.  Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes , 2001, Neuroscience Letters.

[6]  T. van der Poll,et al.  Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia1 , 2002, The Journal of Immunology.

[7]  P. Han,et al.  Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult , 2003, Journal of neuroscience research.

[8]  K. Burgess,et al.  Long-Lasting Rescue of Age-Associated Deficits in Cognition and the CNS Cholinergic Phenotype by a Partial Agonist Peptidomimetic Ligand of TrkA , 2004, The Journal of Neuroscience.

[9]  P. Fisher,et al.  β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression , 2005, Nature.

[10]  Yoshua Bengio,et al.  Selective small molecule peptidomimetic ligands of TrkC and TrkA receptors afford discrete or complete neurotrophic activities. , 2005, Chemistry & biology.

[11]  Pierre J Magistretti,et al.  Neuron-glia metabolic coupling and plasticity. , 2006, The Journal of experimental biology.

[12]  Hideyuki Okano,et al.  Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury , 2006, Nature Medicine.

[13]  H. Wee,et al.  Aspirin-induced blockade of NF-kappaB activity restrains up-regulation of glial fibrillary acidic protein in human astroglial cells. , 2006, Biochimica et biophysica acta.

[14]  J. Lewerenz,et al.  Cooperative action of glutamate transporters and cystine/glutamate antiporter system Xc– protects from oxidative glutamate toxicity , 2006, Journal of neurochemistry.

[15]  Lilia Alberghina,et al.  The modular systems biology approach to investigate the control of apoptosis in Alzheimer's disease neurodegeneration , 2006, BMC Neuroscience.

[16]  Marco Domeniconi,et al.  Pro-NGF secreted by astrocytes promotes motor neuron cell death , 2007, Molecular and Cellular Neuroscience.

[17]  A. Claudio Cuello,et al.  The Failure in NGF Maturation and its Increased Degradation as the Probable Cause for the Vulnerability of Cholinergic Neurons in Alzheimer’s Disease , 2007, Neurochemical Research.

[18]  J. Rothstein,et al.  Focal Transplantation-based Astrocyte Replacement is Neuroprotective in a Model of Motor Neuron Disease , 2008, Nature Neuroscience.

[19]  L. Alberghina,et al.  A New Nerve Growth Factor-Mimetic Peptide Active on Neuropathic Pain in Rats , 2008, The Journal of Neuroscience.

[20]  Honglei Chen,et al.  Peripheral inflammatory biomarkers and risk of Parkinson's disease. , 2007, American journal of epidemiology.

[21]  M. Sofroniew,et al.  Astrocytes: biology and pathology , 2009, Acta Neuropathologica.

[22]  L. Alberghina,et al.  Intrathecal NGF Administration Reduces Reactive Astrocytosis and Changes Neurotrophin Receptors Expression Pattern in a Rat Model of Neuropathic Pain , 2009, Cellular and Molecular Neurobiology.

[23]  S. Barnum,et al.  Transgenic Inhibition of Astroglial NF-κB Improves Functional Outcome in Experimental Autoimmune Encephalomyelitis by Suppressing Chronic Central Nervous System Inflammation1 , 2009, The Journal of Immunology.

[24]  Yang-yang Huang,et al.  Nerve growth factor attenuates proliferation of astrocytes via the p75 neurotrophin receptor , 2009, Glia.

[25]  V. Parpura,et al.  Dual regulation of Ca2+‐dependent glutamate release from astrocytes: Vesicular glutamate transporters and cytosolic glutamate levels , 2009, Glia.

[26]  A. Ciarmiello,et al.  Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  N. Urbán,et al.  BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease , 2010, Gene Therapy.

[28]  Fred H. Gage,et al.  Mechanisms Underlying Inflammation in Neurodegeneration , 2010, Cell.

[29]  Neuron–glia metabolic coupling and plasticity , 2011, Experimental physiology.

[30]  L. Alberghina,et al.  Reactive astrocytosis-induced perturbation of synaptic homeostasis is restored by nerve growth factor , 2011, Neurobiology of Disease.

[31]  Emeran A. Mayer,et al.  Gut feelings: the emerging biology of gut–brain communication , 2011, Nature Reviews Neuroscience.

[32]  L. Alberghina,et al.  Cross‐talk between cell cycle induction and mitochondrial dysfunction during oxidative stress and nerve growth factor withdrawal in differentiated PC12 cells , 2011, Journal of neuroscience research.

[33]  Samik Ghosh,et al.  AlzPathway: a comprehensive map of signaling pathways of Alzheimer’s disease , 2012, BMC Systems Biology.

[34]  G. Burnstock,et al.  Pathophysiology of astroglial purinergic signalling , 2012, Purinergic Signalling.

[35]  M. Rattray,et al.  Riluzole elevates GLT-1 activity and levels in striatal astrocytes , 2012, Neurochemistry International.

[36]  Randy F. Stout,et al.  Glial cells in (patho)physiology , 2012, Journal of neurochemistry.

[37]  Robert G. Miller,et al.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). , 2012, The Cochrane database of systematic reviews.

[38]  J. Lindsay,et al.  Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer’s disease , 2012, Alzheimer's & Dementia.

[39]  Hiroaki Kitano,et al.  Gene regulatory network analysis supports inflammation as a key neurodegeneration process in prion disease , 2012, BMC Systems Biology.

[40]  Min-Yu Sun,et al.  Calcium Signaling and Gliotransmission in Normal vs. Reactive Astrocytes , 2012, Front. Pharmacol..

[41]  L. Alberghina,et al.  Targeting reactive astrogliosis by novel biotechnological strategies. , 2012, Biotechnology advances.

[42]  L. Alberghina,et al.  BB14, a Nerve Growth Factor (NGF)-like peptide shown to be effective in reducing reactive astrogliosis and restoring synaptic homeostasis in a rat model of peripheral nerve injury. , 2012, Biotechnology advances.

[43]  L. Alberghina,et al.  Remodelling of supraspinal neuroglial network in neuropathic pain is featured by a reactive gliosis of the nociceptive amygdala , 2013, European journal of pain.

[44]  Samik Ghosh,et al.  Integrating Pathways of Parkinson's Disease in a Molecular Interaction Map , 2013, Molecular Neurobiology.

[45]  L. Alberghina,et al.  A systems biology road map for the discovery of drugs targeting cancer cell metabolism. , 2014, Current pharmaceutical design.

[46]  A. Verkhratsky,et al.  Astrogliopathology: a central element of neuropsychiatric diseases? , 2014, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.